AI assistant
Sending…
Cardiff Oncology, Inc. — Director's Dealing 2021
May 27, 2021
33967_dirs_2021-05-27_30f484c6-d363-4e93-a448-a1829ec02f79.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Cardiff Oncology, Inc. (CRDF)
CIK: 0001213037
Period of Report: 2021-03-19
Reporting Person: Armitage James O (Director)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2021-03-19 | Common Stock | P | 4000 | $10.8178 | Acquired | 14490 | Direct |
Footnotes
F1: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $10.795 to $10.82, inclusive.
More from Cardiff Oncology, Inc.
Investor Presentation
2026
Jun 3
Legal Proceedings Report
2026
May 29
Legal Proceedings Report
2026
May 19
Earnings Release
2026
May 14
Interim / Quarterly Report
2026
May 14
Board/Management Information
2026
Apr 9
Investor Presentation
2026
Feb 25
Earnings Release
2026
Feb 24
Annual Report
2026
Feb 24
Director's Dealing
2026
Feb 18